NasdaqGS:TXMD

Stock Analysis Report

Executive Summary

TherapeuticsMD, Inc. operates as a women’s health care product company in the United States.

Rewards

Trading at 84.9% below its fair value

Earnings are forecast to grow 61.27% per year

Risk Analysis

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has TherapeuticsMD's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TXMD's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.3%

TXMD

2.5%

US Pharmaceuticals

2.0%

US Market


1 Year Return

-54.8%

TXMD

12.9%

US Pharmaceuticals

23.6%

US Market

Return vs Industry: TXMD underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: TXMD underperformed the US Market which returned 24.7% over the past year.


Shareholder returns

TXMDIndustryMarket
7 Day-1.3%2.5%2.0%
30 Day1.3%3.7%3.9%
90 Day-39.2%16.0%12.0%
1 Year-54.8%-54.8%15.7%12.9%26.2%23.6%
3 Year-57.7%-57.7%40.9%30.8%53.2%43.3%
5 Year-46.0%-46.0%29.7%16.0%75.7%56.3%

Price Volatility Vs. Market

How volatile is TherapeuticsMD's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TherapeuticsMD undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TXMD ($2.45) is trading below our estimate of fair value ($16.25)

Significantly Below Fair Value: TXMD is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TXMD is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: TXMD is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TXMD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TXMD has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is TherapeuticsMD forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

61.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TXMD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: TXMD is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TXMD's is expected to become profitable in the next 3 years.

Revenue vs Market: TXMD's revenue (44.2% per year) is forecast to grow faster than the US market (7.5% per year).

High Growth Revenue: TXMD's revenue (44.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TXMD's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TherapeuticsMD performed over the past 5 years?

-18.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TXMD is currently unprofitable.

Growing Profit Margin: TXMD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TXMD is unprofitable, and losses have increased over the past 5 years at a rate of -18.8% per year.

Accelerating Growth: Unable to compare TXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (36.8%).


Return on Equity

High ROE: TXMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is TherapeuticsMD's financial position?


Financial Position Analysis

Short Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: TXMD has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: TXMD has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: TXMD's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: TXMD has a low level of unsold assets or inventory.

Debt Coverage by Assets: TXMD has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TXMD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TXMD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is TherapeuticsMD's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.6%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate TXMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TXMD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TXMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TXMD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TXMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of TherapeuticsMD's salary, the management and board of directors tenure and is there insider trading?

7.5yrs

Average management tenure


CEO

Rob Finizio (48yo)

8.3yrs

Tenure

0

Mr. Robert G. Finizio, also known as Rob, is the Co-Founder of TherapeuticsMD, Inc. and has been its Chief Executive Officer since October 4, 2011. Mr. Finizio serves as Director of ZyVersa Therapeutics, I ...


CEO Compensation Analysis

Compensation vs Market: Rob's total compensation ($USD0.00) is below average for companies of similar size in the US market ($USD2.53M).

Compensation vs Earnings: Rob's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

7.5yrs

Average Tenure

52yo

Average Age

Experienced Management: TXMD's management team is seasoned and experienced (7.5 years average tenure).


Board Age and Tenure

7.9yrs

Average Tenure

54yo

Average Age

Experienced Board: TXMD's board of directors are considered experienced (7.9 years average tenure).


Insider Trading

Insider Buying: TXMD insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$198,00029 Oct 19
John C. Milligan
EntityIndividual
Role
Member of the Board of Directors
President
Shares72,000
Max PriceUS$2.75
BuyUS$99,00029 Oct 19
Brian Bernick
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares36,000
Max PriceUS$2.75
BuyUS$198,00029 Oct 19
Robert Finizio
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares72,000
Max PriceUS$2.75
BuyUS$27,70026 Aug 19
Angus Russell
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$2.77
BuyUS$95,90020 Aug 19
Robert Finizio
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares35,000
Max PriceUS$2.74
BuyUS$29,30019 Aug 19
John C. Milligan
EntityIndividual
Role
Member of the Board of Directors
President
Shares10,000
Max PriceUS$2.93
BuyUS$98,90015 Aug 19
Angus Russell
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares35,000
Max PriceUS$2.99
BuyUS$9,99814 Aug 19
Jane Barlow
EntityIndividual
Shares3,144
Max PriceUS$3.18
BuyUS$47,40014 Aug 19
John C. Milligan
EntityIndividual
Role
Member of the Board of Directors
President
Shares15,000
Max PriceUS$3.16
BuyUS$15,20013 Aug 19
Thomas Thompson
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares5,000
Max PriceUS$3.04
BuyUS$28,70013 Aug 19
Brian Bernick
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares10,000
Max PriceUS$2.87
BuyUS$155,11912 Aug 19
Robert Finizio
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares52,405
Max PriceUS$2.96
BuyUS$99,87015 May 19
Cooper Collins
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares30,000
Max PriceUS$3.33
BuyUS$8,01614 May 19
Thomas Thompson
EntityIndividual
Role
Chairman of the Board
Independent Chairman of the Board
Shares2,400
Max PriceUS$3.34
SellUS$100,92001 Mar 19
Jules Musing
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares17,400
Max PriceUS$5.80

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Management Team

  • Jason Spitz

    Vice President of Commercial Development & Operations

    • Rob Finizio (48yo)

      Co-Founder

      • Tenure: 8.3yrs
    • John C. Milligan (57yo)

      President

      • Tenure: 8.3yrs
    • Dan Cartwright (61yo)

      CFO & Treasurer

      • Tenure: 8.3yrs
    • Mitchell Krassan (53yo)

      Executive VP and Chief Strategy & Performance Officer

      • Tenure: 8.3yrs
    • Brian Bernick (51yo)

      Co-Founder

      • Tenure: 8.3yrs
      • Compensation: US$1.21m
    • Joel Krasnow

      Chief Scientific Officer and Head of Regulatory Department

      • Tenure: 6.1yrs
    • Nichol Ochsner

      Vice President of Investor Relations

      • Tenure: 2yrs
    • Michael Donegan (51yo)

      Vice President of Finance

      • Tenure: 6.8yrs
    • Adam Miller

      Chief Information Officer

      • Tenure: 1.8yrs

    Board Members

    • Angus Russell (63yo)

      Independent Director

      • Tenure: 4.8yrs
      • Compensation: US$256.29k
    • Marty Carroll (70yo)

      Independent Director

      • Tenure: 4.8yrs
      • Compensation: US$260.79k
    • Tommy Thompson (77yo)

      Independent Chairman of the Board

      • Tenure: 7.7yrs
      • Compensation: US$378.31k
    • Rob Finizio (48yo)

      Co-Founder

      • Tenure: 8.3yrs
    • John C. Milligan (57yo)

      President

      • Tenure: 8.3yrs
    • Cooper Collins (40yo)

      Independent Director

      • Tenure: 7.9yrs
      • Compensation: US$272.54k
    • Nick Segal (37yo)

      Independent Director

      • Tenure: 7.9yrs
      • Compensation: US$252.54k
    • Jules Musing (72yo)

      Independent Director

      • Tenure: 6.7yrs
      • Compensation: US$245.04k
    • Brian Bernick (51yo)

      Co-Founder

      • Tenure: 8.3yrs
      • Compensation: US$1.21m
    • Rob LaPenta (50yo)

      Independent Director

      • Tenure: 7.9yrs
      • Compensation: US$275.04k

    Company Information

    TherapeuticsMD, Inc.'s company bio, employee growth, exchange listings and data sources


    Key Information

    • Name: TherapeuticsMD, Inc.
    • Ticker: TXMD
    • Exchange: NasdaqGS
    • Founded: 2008
    • Industry: Pharmaceuticals
    • Sector: Pharmaceuticals & Biotech
    • Market Cap: US$626.419m
    • Shares outstanding: 271.18m
    • Website: https://www.therapeuticsmd.com

    Number of Employees


    Location

    • TherapeuticsMD, Inc.
    • 6800 Broken Sound Parkway NW
    • Third Floor
    • Boca Raton
    • Florida
    • 33487
    • United States

    Listings

    TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
    TXMDNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2011
    29TDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2011

    Biography

    TherapeuticsMD, Inc. operates as a women’s health care product company in the United States. The company’s hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. In addition, it commercializes IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. 


    Company Analysis and Financial Data Status

    All financial data provided by Standard & Poor's Capital IQ.
    DataLast Updated (UTC time)
    Company Analysis2020/01/19 00:16
    End of Day Share Price2020/01/17 00:00
    Earnings2019/09/30
    Annual Earnings2018/12/31


    Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.